• news and publications | Enterprise Therapeutics | Treatment of respiratory diseases

PUBLICATIONS, NEWS & EVENTS

The pharmacology of novel TMEM16A potentiator compounds

The pharmacology of novel TMEM16A potentiator compounds

Henry…
April 2, 2019/by admin

TMEM16A channel function does not influence goblet cell numbers in the human airway epithelium

TMEM16A channel function does not influence goblet cell numbers…
April 2, 2019/by admin

EACT increases intracellular calcium levels by a TMEM16A-independent mechanism

EACT increases intracellular calcium levels by a TMEM16A-independent…
April 2, 2019/by admin

Enterprise Therapeutics strengthens leadership team, appoints Amit D. Munshi as Non-Executive Chairman

Appointment brings significant commercial pharma experience as…
March 25, 2019/by admin

Gordon Research Conference ‘Modeling and Targeting Mucociliary Function in Health and Disease: Genes to Cells to Interaction Networks and Tissues’ February 2019

Identifying pathways & compounds regulating goblet cell metaplasia…
February 20, 2019/by admin

Enterprise Therapeutics selected as a finalist for Scrip Awards and Lifestars Awards

Scrip Awards 2018 “Financing Deal of the Year- Private”…
October 4, 2018/by admin

32nd Annual North American Cystic Fibrosis Conference (NACFC) 18-20 October-Denver – Submission 210

Submission: 210 - PHARMACOKINETIC AND PHARMACODYNAMIC PROFILE…
September 28, 2018/by admin

32nd Annual North American Cystic Fibrosis Conference (NACFC) 18-20 October-Denver – Submission 89

Submission: 89 - IDENTIFYING PATHWAYS REGULATING GOBLET CELL…
September 28, 2018/by admin

Enterprise Therapeutics raises £29 million ($41 million USD) funding

Brighton, UK – 12 April 2018: Enterprise Therapeutics Ltd (Enterprise),…
April 12, 2018/by admin

Building in vivo potency and duration of action and into a novel inhaled ENaC blocker, ETD001, presented at the European Cystic Fibrosis Society Basic Science Meeting, Loutraki, Greece, March 2018

Inhaled drugs are typically cleared very rapidly from the airway…
March 2, 2018/by admin

Identifying pathways regulating goblet cell metaplasia: phenotypic screening with bronchospheres, presented at the European Cystic Fibrosis Society Basic Science Meeting, Loutraki, Greece, March 2018

It is widely accepted that the composition of mucus in the CF…
March 1, 2018/by admin

The discovery of novel regulators of airway anion secretion, oral communication at the UK Cystic Fibrosis Trust Conference, Nottingham, UK, September 2017

September 1, 2017/by admin

Enterprise is a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases of high unmet medical need and commercial opportunity – the company plans to initiate clinical trials in 2019.

Scientific Strategy

Enterprise is developing muco-regulatory drugs that are expected to help respiratory patients by improving their ability to breath and reduce the number of lung infections they experience leading to a longer and more healthy life.

Learn more

Pipeline

Enterprise has developed a pipeline of novel low molecular weight compounds with first in class potential – our most advanced compounds, which target ion channels in the airway epithelium are expected to enter human trials in late 2019.

Learn more